WO2007052057A3 - Adminstration routes for priming/boosting with influenza vaccines - Google Patents

Adminstration routes for priming/boosting with influenza vaccines Download PDF

Info

Publication number
WO2007052057A3
WO2007052057A3 PCT/GB2006/004132 GB2006004132W WO2007052057A3 WO 2007052057 A3 WO2007052057 A3 WO 2007052057A3 GB 2006004132 W GB2006004132 W GB 2006004132W WO 2007052057 A3 WO2007052057 A3 WO 2007052057A3
Authority
WO
WIPO (PCT)
Prior art keywords
adminstration
priming
boosting
routes
influenza vaccines
Prior art date
Application number
PCT/GB2006/004132
Other languages
French (fr)
Other versions
WO2007052057A2 (en
Inventor
Michael Vajdy
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Michael Vajdy
Derek O'hagan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Michael Vajdy, Derek O'hagan filed Critical Novartis Vaccines & Diagnostic
Priority to NZ567980A priority Critical patent/NZ567980A/en
Priority to AU2006310338A priority patent/AU2006310338A1/en
Priority to CA002628379A priority patent/CA2628379A1/en
Priority to EP06808427A priority patent/EP1945253A2/en
Priority to JP2008538419A priority patent/JP2009514840A/en
Priority to US12/092,225 priority patent/US20100158943A1/en
Publication of WO2007052057A2 publication Critical patent/WO2007052057A2/en
Publication of WO2007052057A3 publication Critical patent/WO2007052057A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patients receive a mucosal influenza vaccine and then receive a parenteral influenza vaccine, in that order, typically during different visits to a vaccination centre.
PCT/GB2006/004132 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines WO2007052057A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NZ567980A NZ567980A (en) 2005-11-04 2006-11-06 Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
AU2006310338A AU2006310338A1 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines
CA002628379A CA2628379A1 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines
EP06808427A EP1945253A2 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines
JP2008538419A JP2009514840A (en) 2005-11-04 2006-11-06 Route of administration for priming / boosting with influenza vaccine
US12/092,225 US20100158943A1 (en) 2005-11-04 2006-11-06 Administration routes for priming/boosting with influenza vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US60/734,026 2005-11-04
US83633206P 2006-08-07 2006-08-07
US60/836,332 2006-08-07

Publications (2)

Publication Number Publication Date
WO2007052057A2 WO2007052057A2 (en) 2007-05-10
WO2007052057A3 true WO2007052057A3 (en) 2007-07-12

Family

ID=37862714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/004132 WO2007052057A2 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Country Status (7)

Country Link
US (1) US20100158943A1 (en)
EP (1) EP1945253A2 (en)
JP (1) JP2009514840A (en)
AU (1) AU2006310338A1 (en)
CA (1) CA2628379A1 (en)
NZ (1) NZ567980A (en)
WO (1) WO2007052057A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500603A (en) * 2006-06-15 2009-08-05 诺华有限公司 Adjuvant-sparing multi-dose influenza vaccination regimen
BRPI0815008B8 (en) * 2007-08-02 2021-05-25 Biondvax Pharmaceuticals Ltd multimeric influenza vaccines with multiple epitopes
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (en) 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
EP2310045A1 (en) * 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
CN102307590A (en) 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2014095866A1 (en) * 2012-12-17 2014-06-26 Eurocine Vaccines Ab Intranasal vaccination dosage regimen
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009648A1 (en) * 1993-10-04 1995-04-13 Gould Fogerite Susan Protein- or peptide-cochleate vaccines and methods of immunizing using the same
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
WO2004075829A2 (en) * 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
IL148672A0 (en) * 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009648A1 (en) * 1993-10-04 1995-04-13 Gould Fogerite Susan Protein- or peptide-cochleate vaccines and methods of immunizing using the same
WO2004075829A2 (en) * 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Entscheidende Daten der Phase-III-Studie zeigen: Der mittels Zellkultur hergestellte Grippeimpfstoff von Novartis ist gut verträglich und wirksam", INTERNET ARTICLE, 19 October 2006 (2006-10-19), XP002425539, Retrieved from the Internet <URL:http://www.influenza.de/grippe/news/00122/00184/index.html> [retrieved on 20070319] *
BARCHFELD G L ET AL: "The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 7-8, 26 February 1999 (1999-02-26), pages 695 - 704, XP004154808, ISSN: 0264-410X *
COX R J ET AL: "Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY JAN 2004, vol. 59, no. 1, January 2004 (2004-01-01), pages 1 - 15, XP002427580, ISSN: 0300-9475 *
DEL GIUDICE G ET AL: "What are the limits of adjuvanticity?", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, 15 October 2001 (2001-10-15), pages S38 - S41, XP004307329, ISSN: 0264-410X *
JOSEPH A ET AL: "Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 27-28, 10 September 2002 (2002-09-10), pages 3342 - 3354, XP004378529, ISSN: 0264-410X *
MORAN T M ET AL: "Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.", THE JOURNAL OF INFECTIOUS DISEASES SEP 1999, vol. 180, no. 3, September 1999 (1999-09-01), pages 579 - 585, XP002426088, ISSN: 0022-1899 *
PIEN H: "Statement presented to committee on aging United States Senate", INTERNET ARTICLE, 28 September 2004 (2004-09-28), pages 1-15, XP002425556, Retrieved from the Internet <URL:http://aging.senate.gov/_files/hr133hp.pdf> [retrieved on 20070320] *
See also references of EP1945253A2 *
VAJDY M. ET AL.: "A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza", CLINICAL IMMUNOLOGY, 8 March 2007 (2007-03-08), XP002426595, Retrieved from the Internet <URL:http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WCJ-4N6Y5ND-1&_user=987766&_coverDate=03%2F08%2F2007&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000049880&_version=1&_urlVersion=0&_userid=987766&md5=6cb2137684d4fa2cf57ffe4a94682e92> [retrieved on 20070322] *
VAJDY MICHAEL ET AL: "Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.", IMMUNOLOGY SEP 2003, vol. 110, no. 1, September 2003 (2003-09-01), pages 86 - 94, XP002426598, ISSN: 0019-2805 *
VAJDY MICHAEL ET AL: "Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.", AIDS RESEARCH AND HUMAN RETROVIRUSES NOV 2004, vol. 20, no. 11, November 2004 (2004-11-01), pages 1269 - 1281, XP002426597, ISSN: 0889-2229 *
VERMOUT S ET AL.: "Choix d'un adjuvant lors d'essais de vaccination", vol. 147, 2003, pages 393 - 401, XP002426100, Retrieved from the Internet <URL:http://www.facmv.ulg.ac.be/amv/articles/2003_147_6_03.pdf> [retrieved on 20070320] *
WILLIAMS ANDREW EVAN ET AL: "Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2004, vol. 173, no. 12, 15 December 2004 (2004-12-15), pages 7435 - 7443, XP002426599, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2628379A1 (en) 2007-05-10
NZ567980A (en) 2012-01-12
AU2006310338A1 (en) 2007-05-10
EP1945253A2 (en) 2008-07-23
WO2007052057A2 (en) 2007-05-10
JP2009514840A (en) 2009-04-09
US20100158943A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
WO2007052057A3 (en) Adminstration routes for priming/boosting with influenza vaccines
WO2010066418A8 (en) Use of flt3 ligand for strengthening immune responses in rna immunization
WO2007144772A3 (en) Adjuvant-sparing multi-dose influenza vaccination regimen
DK1737485T3 (en) VACCINE WITH MUCINOUS GLYCOPROTEIN (MUC-1)
IL204361A (en) Method for producing the flu virus and a flu vaccine obtained using said method
HK1219417A1 (en) Method of treating patients with a mucinous glycoprotein (muc-1) vaccine (muc-1)
EP1766096A4 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
GB2451216B (en) A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
WO2007111940A3 (en) Regimens for immunisation with meningococcal conjugates
EP2351581A4 (en) A vaccine composition against foot-and-mouth disease and the preparation method thereof
MA28885B1 (en) vaccines
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
BRPI0811499A2 (en) METHODS FOR PURIFYING A VIRAL VIRUS OR ANTIGEN, AND FOR PREPARING A VACCINE AGAINST A VIRAL VIRUS OR ANTIGEN.
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
AP2167A (en) Multivalent avian influenza vaccines.
EP2329845A4 (en) Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration
WO2013052095A3 (en) Vaccine
AP2011005954A0 (en) Vaccine against African horse sickness virus.
WO2008033500A3 (en) Carbohydrate-based vaccines for hiv
GB2444676A (en) Adjuvanted vaccine
ATE503491T1 (en) IMPROVED ANTHRAX VACCINES AND DELIVERY METHODS
HK1122997A1 (en) Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
WO2010093537A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2012125525A3 (en) Equine rhinitis vaccine
WO2010032138A3 (en) Vaccine adjuvant combinations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008538419

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2628379

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 567980

Country of ref document: NZ

Ref document number: 2006310338

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006808427

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006310338

Country of ref document: AU

Date of ref document: 20061106

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006310338

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006808427

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12092225

Country of ref document: US